Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Bio-Techne Corporation (TECH)

72.67 +0.01 (+0.01%)
At close: November 2 at 4:00:00 PM EST
72.67 0.00 (0.00%)
After hours: November 2 at 4:01:03 PM EST
Trade TECH on Coinbase
Chart Range Bar
Loading chart for TECH

What's happening with TECH?

10m ago
Powered by Yahoo Scout

Bio-Techne is approaching its fiscal first-quarter earnings report while operating under a proposed $73-per-share cash acquisition by Merck KGaA. The deal has shareholder approval, and closing is expected in late 2026 or early 2027, subject to remaining conditions. The latest available market data shows 0.00% in pre-market trading against the prior closeon November 3.

Powered by Yahoo Scout
  • Previous Close 72.66
  • Open 72.67
  • Bid 66.89 x 200
  • Ask 78.52 x 200
  • Day's Range 72.66 - 72.72
  • 52 Week Range 43.20 - 72.75
  • Volume 2,016,423
  • Avg. Volume 2,821,681
  • Market Cap (intraday) 11.413B
  • Beta (5Y Monthly) 1.27
  • PE Ratio (TTM) 62.65
  • EPS (TTM) 1.16
  • Earnings Date (est.) Nov 9, 2026
  • Forward Dividend & Yield 0.32 (0.44%)
  • 1y Target Est 70.50
  • Morningstar Rating Rating available with Stock Picks access

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

www.bio-techne.com

3,000

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TECH
24.10%
S&P 500 (^GSPC)
10.17%

1-Year Return

TECH
16.80%
S&P 500 (^GSPC)
10.25%

3-Year Return

TECH
33.22%
S&P 500 (^GSPC)
74.66%

5-Year Return

TECH
40.91%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 321.19M
Earnings 54.62M
Profit Margin 17.01%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

0
100M
200M
300M
13.0%
14.0%
15.0%
16.0%
17.0%

Analyst Insights

View More

Analyst Price Targets

50.00 Low
70.50 Average
72.67 Current
73.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst Wells Fargo
Rating Action Downgrade
Rating Equal-Weight
Price Action Raises
Price Target 62 -> 73

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.97%

  • Return on Assets (ttm)

    6.67%

  • Return on Equity (ttm)

    9.03%

  • Revenue (ttm)

    1.22B

  • Net Income Avi to Common (ttm)

    181.84M

  • Diluted EPS (ttm)

    1.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    265.48M

  • Total Debt/Equity (mrq)

    13.71%

  • Levered Free Cash Flow (ttm)

    229.65M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: